Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 119

Results For "CRO"

4437 News Found

ekincare raises investment from MSD IDEA Studio Asia Pacific
News | April 30, 2025

ekincare raises investment from MSD IDEA Studio Asia Pacific

ekincare has raised a total funding of $22M since 2015 till date


Indegene posts Q4 FY25 consolidated PAT at Rs. 117.6 Cr
News | April 29, 2025

Indegene posts Q4 FY25 consolidated PAT at Rs. 117.6 Cr

The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025


Thermo Fisher Scientific to invest $2 billion to expand US operation
News | April 29, 2025

Thermo Fisher Scientific to invest $2 billion to expand US operation

Investment demonstrates confidence in America’s commitment to science and innovation


Pfizer Q1 2025 revenue drops 8% to $13.7 billion
News | April 29, 2025

Pfizer Q1 2025 revenue drops 8% to $13.7 billion

Delivers robust earnings performance, successfully navigating a dynamic environment


Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr
News | April 28, 2025

Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr

The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025


Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
Biopharma | April 28, 2025

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide


CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Drug Approval | April 28, 2025

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein


We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
News | April 25, 2025

We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer

Bayer expects 2025 to be the most difficult year of its turnaround


Briefs: Ami Organics and Panacea Biotec
News | April 25, 2025

Briefs: Ami Organics and Panacea Biotec

Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan


Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences
News | April 25, 2025

Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences

The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations